Related Experiment Videos
Timentin therapy for Staphylococcus aureus infections in children: results of a multicenter trial
1University of Arkansas for Medical Sciences, Little Rock.
Insights
Ticarcillin/potassium clavulanate (Timentin) effectively treated pediatric Staphylococcus aureus bone, joint, skin, and soft tissue infections. High cure rates and bacteriologic success were observed in multicenter trials.
Area of Science:
- Pediatric Infectious Diseases
- Antimicrobial Therapy
- Clinical Microbiology
Background:
- Staphylococcus aureus is a common cause of pediatric infections.
- Ticarcillin/potassium clavulanate (Timentin) is an antibiotic combination used for bacterial infections.
Purpose of the Study:
- To evaluate the clinical efficacy of Timentin in treating pediatric bone, joint, skin, and soft tissue infections caused by Staphylococcus aureus.
Main Methods:
- Multicenter trials conducted between 1983 and 1986.
- Inclusion of children with culture-confirmed Staphylococcus aureus infections.
- Treatment with Timentin for varying durations based on infection type.
Main Results:
- High clinical cure rates for bone and joint infections (11/16) and skin/soft tissue infections (22/32).
- Excellent bacteriologic cure rates (11/11 for bone/joint, 32/32 for skin/soft tissue).
- Successful treatment of three cases of S. aureus bacteremia.
Conclusions:
- Timentin demonstrated significant clinical and bacteriologic efficacy in treating pediatric S. aureus infections.
- The antibiotic was effective against S. aureus isolates, including those producing beta-lactamase and resistant to ticarcillin alone.
- Timentin is a viable treatment option for these pediatric infections.
Abstract:
Multicenter trials of ticarcillin/potassium clavulanate (Timentin) for bone, joint, skin and soft tissue infections in children were performed from 1983 to 1986. Fifty children with culture-confirmed Staphylococcus aureus infections were identified. Sixteen children (ages 6.2 +/- 3.9 years) with bone and joint infections received Timentin for 8.7 +/- 2.4 days with 11 of 16 cures, 5 of 16 improved, 11 of 11 bacteriologic cures and 3.9 +/- 3.5 days of fever. Thirty-two children (ages 5.7 +/- 3.5 years) with skin and soft tissue infections received Timentin for 5.3 +/- 1.6 days with 22 of 32 cures, 10 of 32 improved, 32 of 32 bacteriologic cures and 1.4 +/- 1.3 days of fever. Three patients had S. aureus bacteremia; all were clinical and bacteriologic cures. All S. aureus isolates were susceptible to Timentin, 18 of 23 isolates tested produced beta-lactamase and 21 of 44 isolates tested were resistant to ticarcillin. The purpose of this report is to describe the clinical efficacy of Timentin in treating these types of S. aureus infections in children.